Abstract

The goal ofthe University of lowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Career Development Program (CDP) is to develop knowledgeable, well-trained scientists experienced in multidisciplinary research for future studies in translational lymphoma research. The provision of ample opportunities for training and career enhancement is a top priority ofthe University of lowa and Mayo Clinic scientific communities. The CDP represents a key

Public Health Relevance

The UI/MC SPORE CDP will provide support for integrated training and education to new investigators committed to careers in lymphoma translational research. The CDP is designed to provide breadth and flexibility to awardees who require additional research knowledge and skills in order to compete for independent extramural grant support and contribute to the UI/MC SPORE. The CDP has been very successful over the last 9 years at accomplishing these goals. The CDP will continue as a research experience under the mentorship of established SPORE investigators and supported by SPORE-funded Core resources.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA097274-11
Application #
8395843
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2002-09-11
Project End
2017-06-30
Budget Start
2012-09-12
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$100,216
Indirect Cost
$26,202

  Institution

Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242

  Publications

Maurer, Matthew J; Ghesquières, Hervé; Link, Brian K et al. (2018) Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol 36:1603-1610
Huet, Sarah; Tesson, Bruno; Jais, Jean-Philippe et al. (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19:549-561
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Tracy, Sean I; Habermann, Thomas M; Feldman, Andrew L et al. (2018) Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica 103:297-303
Mackrides, Nicholas; Chapman, Jennifer; Larson, Melissa C et al. (2018) Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol :
McPhail, Ellen D; Maurer, Matthew J; Macon, William R et al. (2018) Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 103:1899-1907
Hill, Brian T; Nastoupil, Loretta; Winter, Allison M et al. (2018) Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol :
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
J Pelletier, Daniel; O'Donnell, Michael; Stone, Mary Seabury et al. (2018) Intravesicular taxane-induced dermatotoxicity in a 78-year-old man with urothelial carcinoma and primary cutaneous anaplastic large cell lymphoma. J Cutan Pathol 45:453-457
Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598

Showing the most recent 10 out of 387 publications